Press Room
30 June 2013
Redistribution of market shares in the hemophilia market of recombinant coagulation factors due to new approvals and differential profiles
Time-to-market is a key success factor for novel recombinant coagulation factors from new market entrants and established marketers STUTTGART, Germany I July 1, 2013 I Last week the FDA approved Baxter’s novel recombinant factor IX (rFIX) product RIXUBIS as the…
Read more9 May 2013
Blockbuster Biologics 2012: sales are double that of 2006 driven by strong growth of recombinant antibodies
STUTTGART, Germany | May 9, 2013 | The Business Intelligence firm La Merie Publishing released its new compilation of recombinant antibody and protein sales, this time for the year 2012. Since the first edition of this report, total sales of…
Read more19 March 2012
The huge potential of GLP-1 receptor agonists in the diabetes market opens opportunities for technology providers and Big Pharma
Weight reduction as unique feature of GLP-1R agonists Results of cardiovascular outcomes studies eagerly awaited Demonstration of protective effect on beta cells could further boost the market potential
Read more24 November 2011
Blockbuster Drugs 2010: small molecules still dominating, but biologics strongly emerging
100 blockbuster drugs with combined sales of US$ 249 bln; 61% small molecule blockbusters with US$ 150 bln compared with US$ 85 bln for 31 biologic blockbusters
Read more26 October 2011
Fierce Competition Requires Precision in Meeting the Needs of the Coagulation Factor Market
With potentially more than 20 products in the recombinant coagulation factors market within 5 to 6 years, it will be mandatory to meet the needs of a US$ 6.2 bln market in 2010 in order to gain a relevant market…
Read more16 September 2011
Antibody-Drug Conjugates 2011 – real breakthrough still to come
Many good news (accelerated approval, impressive tumor response rates, strong pipeline fill-up, reasonable attrition rate) for the complex antibody-drug conjugate technology, but final technological, clinical and comercial validation needed
Read more7 March 2011
Biologics Sales in 2010 exceeded US$ 100 bln
Growth drivers were therapeutic antibodies; single digit growth for most therapeutic proteins; novel anti-inflammatory antibodies continue strong growth; number of blockbuster biologics increased to 30
Read more8 September 2010
The Product Portfolio Strategy as Decisive Force in Forming the Future Coagulation Factor Market
With over US$ 5.5 bln sales in 2009, the five recombinant products of coagulation factors VIII, IX and VIIa attracted more than 41 projects in the R&D pipeline, 12 of them already in the clinic, 7 within one year, and…
Read more14 August 2009
Changes ahead in the coagulation factor market by new entrants and technologies
The worldwide market of recombinant and plasma derived coagulation factors grew to more than US$ 7.5 bln in 2008 and will be fundamentally challenged by over 40 projects in the R&D pipeline
Read more11 November 2008
Trends in the diabetes drug pipeline 2008
Increasing prevalence of diabetes and an attractive market foster intense efforts in improving existing approaches and exploring new treatment modalities
Read more28 October 2008
The future of human insulin: tailored and oral
Prevailing human insulin analogs to be followed by tailored insulin analogs and insulins with optimized drug delivery solutions
Read more7 October 2008
Human growth hormone (hGH): biosimilar pricing is not enough, convenience will mandate
After approval of three biosimilar hGH products, the pipeline is full of next generation hGH products with less frequent injection or non-injectable delivery
Read moreFeatured Reports
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
RElated News